En savoir plus sur le livre
Over the last decade, biologic agents have transformed the management of chronic inflammatory diseases like rheumatoid arthritis, Crohn’s disease, and psoriasis. Understanding the complex cytokine network and their roles in these disorders has been pivotal for advancing targeted biologic therapies. TNF-? is particularly significant in the pathogenesis of various chronic inflammatory diseases, with elevated levels observed in conditions such as Crohn’s disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis, indicating its involvement in their development. While TNF-? is essential for activating immune responses, its persistent production can lead to chronic inflammation and tissue damage. This volume offers a comprehensive overview of the development, pharmacology, efficacy, and safety of current TNF-? inhibitors, including etanercept, infliximab, and adalimumab. The first three chapters establish a foundation on TNF-? and its inhibition, starting with an introduction to TNF and its pathophysiology in Chapter 1. Chapter 2 chronicles the history of TNF inhibitor development, while Chapter 3 delves into the pharmacology of these agents.
Achat du livre
TNF-alpha inhibitors, Jeffrey M. Weinberg
- Langue
- Année de publication
- 2006
- product-detail.submit-box.info.binding
- (rigide)
Modes de paiement
Personne n'a encore évalué .